Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther
Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.
How this was made
The 30-second read
Why it matters
The key tradable elements are the lowered 2026 revenue guidance range and the improved operating expense guidance, alongside quantified commercial momentum (RUCONEST active patient base, Joenja revenue growth) and a defined catalyst window for larger leniolisib CVID-related readouts in Q4 2026.
Market read
A guidance reset with quantified commercial performance and upcoming clinical/regulatory milestones can drive repricing of near-term revenue expectations and longer-dated pipeline optionality.
What to watch
The excerpt cites operating profit pressure from inventory impairments and a France site closure; traders may need to assess whether these are one-offs or indicate structural cost issues.
Background
Pharming Group N.V. is updating investors on Q2 and H1 2026 performance for its commercial rare-disease portfolio (RUCONEST, Joenja/leniolisib) and providing revised full-year 2026 guidance plus upcoming regulatory and clinical milestones.
Ticker impact
Pharming reports Q2 and H1 2026 results, revises 2026 revenue guidance to $375M-$395M, and highlights RUCONEST and Joenja momentum plus upcoming clinical readouts.
Likely choppy reaction: downside from lowered revenue guidance, partially offset by Joenja growth and clearer catalysts into Q4 2026.
The article contains a concrete guidance revision and multiple operating drivers (RUCONEST stabilization expectations, Joenja growth, FDA action date, and planned Q4 trial readouts). However, it is a preliminary/unaudited results update, and the excerpt does not include the full financial statements or consensus context.
Market effects
Reinforces investor focus on rare-disease commercial execution plus pipeline catalysts (leniolisib) rather than only near-term revenue stability.
Limited; primarily affects European biotech sentiment given Euronext listing and Netherlands-based issuer.
Moderate for global rare-disease investors due to upcoming immunodeficiency readouts and regulatory timeline (PDUFA target).
Counterpoint
The revenue guidance cut could reflect temporary manufacturing or channel normalization effects, while RUCONEST active patients and Joenja paid-therapy growth suggest underlying demand remains intact.
Key entities
- companyPharming Group N.V.
Issuer reporting Q2 and first-half 2026 financial results, revising 2026 guidance, and outlining commercial and clinical catalysts for RUCONEST and Joenja (leniolisib).
- productRUCONEST
On-demand IV HAE treatment; Q2 2026 revenue and active patient base trends are used to support stabilization expectations for H2 2026.
- productJoenja (leniolisib)
APDS treatment with expanding geographies and growth; article details FDA pediatric sNDA resubmission and PDUFA target plus planned broader-population trial readouts.
- regulatorFDA
Accepted the resubmitted pediatric sNDA for Joenja with a PDUFA target action date of October 24, 2026.
